Page last updated: 2024-12-05

sulfamerazine

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Sulfamerazine is a sulfonamide antibiotic used to treat bacterial infections. It was first synthesized in the 1940s and acts by inhibiting the synthesis of dihydrofolic acid, a key precursor in bacterial metabolism. Sulfamerazine is effective against a wide range of Gram-positive and Gram-negative bacteria, and it is commonly used to treat urinary tract infections, pneumonia, and other respiratory infections. Due to its effectiveness and low cost, sulfamerazine continues to be studied for its potential therapeutic uses, especially in the treatment of multi-drug resistant bacterial infections.'

Cross-References

ID SourceID
PubMed CID5325
CHEMBL ID438
CHEBI ID102130
SCHEMBL ID33999
MeSH IDM0020746

Synonyms (207)

Synonym
BRD-K93524252-001-05-6
4-amino-n-(4-methyl-pyrimidin-2-yl)-benzenesulfonamide
smr000145672
MLS000551747 ,
n(sup1)-(4-methyl-2-pyrimidinyl)sulfanilamide
127-79-7
percoccide
metilsulfazin
2-(4-aminobenzenesulfonamido)-4-methylpyrimidine
sulfamerazine ,
septacil
nsc-27259
veta-merazine
septosyl
sulfameradine
sulfamerazin
n-(4-methyl-2-pyrimidyl)sulfanilamide
mesulfa
a-310
methylpyrimal
benzenesulfonamide, 4-amino-n-(4-methyl-2-pyrimidinyl)-
2-sulfanilamido-4-methylpyrimidine
2-sulfa-4-methylpyrimidine
2(p-aminobenzolsulfonamido)-4-methylpyrimidin
kelamerazine
cremomerazine
debenal-m
methylsulfazine
rp 2632
sulfamethyldiazine
metilsulfadiazin
sumedine
pyrimal m
solumedin
sulfanilamide, n1-(4-methyl-2-pyrimidinyl)-
pyralcid
nsc27259
sulphamerazine
pirimal-m
romezin
2632 r. p.
2643-rp
mebacid
DIVK1C_000563
KBIO1_000563
SPECTRUM_000003
PRESTWICK_17
cas-127-79-7
NCGC00016386-01
BSPBIO_000847
IDI1_000563
4-amino-n-(4-methylpyrimidin-2-yl)benzenesulfonamide
4-amino-n-(4-methyl-2-pyrimidinyl)benzenesulfonamide
PRESTWICK3_000694
BSPBIO_002886
PRESTWICK2_000694
AB00052096
2-(sulfanilamido)-4-methylpyrimidine
n(1)-(4-methyl-2-pyrimidinyl)sulfanilamide
DB01581
4-amino-n-(4-methyl-2-pyrimidinyl)-benzenesulfonamide
2-(p-aminobenzolsulfonamido)-4-methylpyrimidine
sulfamerazine (inn)
D02435
NCGC00094787-02
NCGC00094787-01
sulfamerazina [inn-spanish]
methylsulfazin
einecs 204-866-2
nsc 27259
ai3-08026
n(sup 1)-(4-methyl-2-pyrimidinyl)sulfanilamide
n1-(4-methyl-2-pyrimidinyl)sulfanilamide
brn 0249133
solfamerazina [dcit]
sulfanilamide, n(sup 1)-(4-methyl-2-pyrimidinyl)-
sulfamerazinum [inn-latin]
(p-aminobenzolsulfonyl)-2-amino-4-methylpyrimidin [german]
KBIO2_002911
KBIOGR_000745
KBIOSS_000343
KBIO3_002106
KBIO2_005479
KBIO2_000343
SPBIO_001419
SPECTRUM2_001320
NINDS_000563
SPECTRUM3_001363
PRESTWICK1_000694
SPECTRUM4_000343
PRESTWICK0_000694
SPBIO_002768
SPECTRUM1500547
SPECTRUM5_001413
BPBIO1_000933
MLS001201765
sulfamerazine, reagentplus(r), >=99.0%
HMS2092I17
CHEMBL438
sulfamerazine (trisulfapyrimidines)
AKOS005143010
HMS501M05
HMS1921A15
HMS1570K09
sulfamerazinum
sulfamerazina
(p-aminobenzolsulfonyl)-2-amino-4-methylpyrimidin
CHEBI:102130 ,
A805747
HMS2097K09
BBL003544
4-amino-n-(4-methylpyrimidin-2-yl)benzene-1-sulfonamide
STK520614
nsc-757325
nsc757325
pharmakon1600-01500547
dtxcid603612
dtxsid0023612 ,
tox21_110411
solfamerazina
HMS2234D16
CCG-39258
NCGC00016386-02
NCGC00016386-03
unii-ur1sab295f
sulfamerazine [usp:inn:ban]
5-25-10-00167 (beilstein handbook reference)
ur1sab295f ,
FT-0645132
FT-0631745
sulfadimidine impurity a [ep impurity]
triple sulfoid component sulfamerazine
sulfose component sulfamerazine
n(sup 1)-(4-methyl-2- pyrimidinyl)sulfanilamide
sulfamerazine component of sulfose
sulfamerazine component of lantrisul
lantrisul component sulfamerazine
sulfamerazine [vandf]
terfonyl component sulfamerazine
sulfamerazine [orange book]
sulfamerazine component of sulfaloid
sulfaloid component sulfamerazine
sulfamerazine [usp-rs]
neotrizine component sulfamerazine
sulfamerazine [who-dd]
sulfamerazine component of neotrizine
sulfamerazine [mi]
trisulfapyrimidines (sulfamerazine) [orange book]
sulfamerazine [green book]
sulfamerazine [ep monograph]
sulfamerazine [mart.]
sulfamerazine component of terfonyl
trisulfapyrimidines (sulfamerazine)
sulfamerazine component of triple sulfoid
sulfamerazine [inn]
EPITOPE ID:122236
S3132
HMS3374K04
HY-B0512
AB00052096-13
SCHEMBL33999
NCGC00016386-06
tox21_110411_1
KS-5323
Q-201761
n'-(4-methyl-2-pyrimidyl) sulfanilamide
2-(p-aminobenzosulfonamido)-4-methylpyrimidine
AB00052096_16
AB00052096_15
OPERA_ID_988
mfcd00023212
F2190-0484
rp2632
SR-01000684857-4
SR-01000684857-2
sr-01000684857
sulfamerazine, united states pharmacopeia (usp) reference standard
sulfamerazine, vetranal(tm), analytical standard
HMS3652I03
sulfamerazine, pharmaceutical secondary standard; certified reference material
sulfamerazine, vetec(tm) reagent grade, 98%
sulfamerazine, european pharmacopoeia (ep) reference standard
4-amino-n-(4-methyl-2-pyrimidyl)benzenesulfonamide; sulfamerazine; sulfadimidine imp. a (pharmeuropa); sulfadimidine impurity a
SBI-0051521.P003
HMS3714K09
SW196334-3
Q415196
n1-(4-methylpyrimidin-2-yl)sulfanilamide
sulfamerazine-13c6
sulfamerazine 100 microg/ml in acetonitrile
AMY23374
BRD-K93524252-001-15-5
4-amino-n-(4-methylpyrimidin-2-yl)
D84140
sulfamerazine 1000 microg/ml in acetonitrile
EN300-202655
gtpl12640
Z1954804578
sulfamerazine (usp-rs)
sulfamerazine (ep monograph)
sulfamerazine (mart.)
sulfamerazinum (inn-latin)
sulfadimidine impurity a (ep impurity)
sulfamerazina (inn-spanish)
sulfamerazine (usp:inn:ban)
monomethylsulfadiazine
sulfamerazine fish grade

Research Excerpts

Overview

Sulfamerazine (SM) is a commonly used antibiotic. It has been widely used to control various bacterial infectious diseases.

ExcerptReferenceRelevance
"Sulfamerazine (SM) is a commonly used antibiotic and have been widely used to control various bacterial infectious diseases. "( The characteristics of CDOM structural composition and the effect on indirect photodegradation of sulfamerazine.
Bai, Y; Cui, H; Cui, Z; Ding, D; Hong, C; Hu, Q; Qu, K; Zhou, M, 2023
)
2.57

Pharmacokinetics

Sulfamerazine, 4- hydroxysulfamerazines and N4-acetyl-4-hydroxylfuryl sulfamerazine. Biosynthesis in the dog, isolation, identification by MS and NMR, TLC (Rf values) and HPLC (capacity factors and molar extinction) Half-life of elimination, metabolism, renal excretion and protein binding in dog.

ExcerptReferenceRelevance
" A two-compartment pharmacokinetic model was developed to describe the disposition of sulfamerazine."( Disposition of sulfonamides in food-producing animals: pharmacokinetics of sulfamerazine in ewe lambs.
Bevill, RF; Bourne, DW; Hayashi, M; Koritz, GD, 1979
)
0.71
" According to the different elimination mechanisms of the drugs investigated the kinetics was infleunced in different way by the restriction of the renal elimination of these drugs: The half-life periods for the elimination of Metindol, Nevigramon and Mebacid remained unchanged in patients with renal diseases; the half-value period for the elimination of Sulfaclomid was prolonged."( [Studies on the pharmacokinetics of Sulfaclomid, Mebacid, Nevigramon and Metindol in patients with reduced kidney function].
Stein, G; Traeger, A, 1978
)
0.26
" The elimination half-life (beta-phase) of the sulphonamides in plasma varied from 70 to 1000 min and was positively correlated with the solubility of the compounds in organic solvents."( Half-life, apparent volume of distribution and protein-binding for some sulphonamides in cows.
Nielsen, P; Rasmussen, F, 1977
)
0.26
" Difference in elimination half-life of SMZ, SMR, and SDZ could be related to difference in metabolism and renal clearance values."( Pharmacokinetics and renal clearance of sulfamethazine, sulfamerazine, and sulfadiazine and their N4-acetyl and hydroxy metabolites in horses.
Baakman, M; Firth, EC; Nouws, JF; Vree, TB, 1987
)
0.52
"For the following compounds: sulfamerazine, 4- hydroxysulfamerazine , N4- acetylsulfamerazine , N4-acetyl-4- hydroxysulfamerazine , the following data are reported: biosynthesis in the dog, isolation, identification by MS and NMR, TLC (Rf values) and HPLC (capacity factors and molar extinction), half-life of elimination, metabolism, renal excretion and protein binding in dog."( Isolation and identification of 4-hydroxysulfamerazine and preliminary studies on its pharmacokinetics in dogs.
Hekster, YA; Nouws, JF; Tijhuis, MW; Vree, TB, 1984
)
0.82
" Pharmacokinetic analysis was based upon "one compartment model"."( Pharmacokinetic analysis of the level of sulfonamide-trimethoprim combination in calves.
Duda, M; Roliński, Z,
)
0.13
" The half-life of elimination of sulphamerazine is 12 h in 'fast' and 24 h in 'slow' acetylators."( Pharmacokinetics, acetylation-deacetylation, renal clearance, and protein binding of sulphamerazine, N4-acetylsulphamerazine, and N4-trideuteroacetylsulphamerazine in 'fast' and 'slow' acetylators.
Baakman, M; Hekster, CA; Janssen, T; Oosterbaan, M; Termond, E; Tijhuis, M; Vree, TB,
)
0.13
"The mathematical foundations underlying pharmacokinetic testing and acceptance of medicaments for domestic mammals are expounded and discussed, with reference being made to examples of intramuscular, subcutaneous, and oral application of Mebacid 200 and Mebacid tablets."( [Pharmacokinetic model studies of sulfamerazine in domestic mammals. 2. Elimination of Mebacid 200 and Mebacid tablets following oral, subcutaneous and intramuscular administration].
Heinze, W; Lender, S; Losch, K; Mieth, K, 1980
)
0.54
"The pharmacokinetic properties of sulphamerazine, following oral application of granulated Mebacid to cattle, calf, and sheep, were compared with results obtained from the use of Mebacid tablets."( [Pharmacokinetic findings following the oral application of granulated Mebacid in cattle, calves and sheep].
Lender, S; Losch, K; Mieth, K, 1981
)
0.26
" Exponential excretion was recorded from all species, according to the following equation: c = B x e-k2 x t The most favourable pharmacokinetic parameters were recorded from calf."( [Pharmacokinetic model studies of sulfamerazine in domestic mammals. 1. Elimination of Mebacid 200 following intravenous administration to large animals].
Heinze, W; Lender, S; Losch, K; Mieth, K, 1980
)
0.54
" Therefore, due allowance must be made, by means of unilateral confidence, of the most unfavourable case of high protein fixation, low half-life for elimination, and high coefficient of distribution."( [Pharmacokinetic model studies of sulfamerazine in domestic mammals. 4. Mebacid tablet and Mebacid 200 dosage calculation problems].
Heinze, W; Losch, K; Mieth, K, 1980
)
0.54
"The problem of no residues is elucidated and discussed under pharmacokinetic aspects."( [Pharmacokinetic model studies of sulfamerazine in domestic mammals. 6. Absence of drug residues].
Heinze, W; Losch, K; Mieth, K, 1980
)
0.54
"The pharmacokinetic properties of sulphaperine-sodium, Mebacid 200, and sulphadimidine-sodium were experimentally established from fowl and mathematically objectivated."( [Pharmacokinetic studies of sulfamerazine-Na, sulfaperine-Na and sulfadimidine-Na in the hen].
Losch, K, 1980
)
0.56

Compound-Compound Interactions

ExcerptReferenceRelevance
" On the basis of literature data six sulphonamides, sulphadiazine, sulphachloropyridazine, sulphamethoxazole, sulphaisodimidine, sulphamerazine and sulphamethomidine appeared particularly suitable for combination with trimethoprim."( Development of sulphonamide-trimethoprim combinations for urinary tract infections. Part I: Comparison of the antibacterial effect of sulphonamides alone and in combination with trimethoprim.
Bergan, T; Ekström, B; Forsgren, U; Ortengren, B, 1979
)
0.26
"Bacterial growth kinetics and checkerboard titration experiments have been performed to determine the inhibitory power of metioprim (I) and brodimoprim (II) alone and in combination with diaminodiphenylsulfone (DDS) using Escherichia coli and mycobacteria as test organisms."( Bacterial growth kinetics of Escherichia coli and mycobacteria in the presence of brodimoprim and metioprim alone and in combination with sulfamerazine and dapsone (VI).
Rosenfeld, M; Seydel, JK; Wempe, EG, 1983
)
0.47

Bioavailability

ExcerptReferenceRelevance
"The bioavailability of seven commercial trisulfapyrimidine suspensions was studied in 14 adult male volunteers."( Bioavailability and dissolution behavior of trisulfapyrimidine suspensions.
Barry, H; Colaizzi, JL; Goehl, TJ; Jaffe, JM; Mathur, LK; Poust, RI; Shah, VP, 1979
)
0.26
" After sulfamerazine was given orally, there was a marked evolution in the shape of the concentration-time curves in function of age, strongly suggesting a defective absorption rate in the first weeks after birth."( Pharmacokinetics of sulfamerazine and antipyrine in neonatal and young lambs.
Belpaire, FM; Bogaert, MG; De Backer, P; Debackere, M, 1982
)
1.04
" The absorption rate constant (Kab) of each sulfonamide increased with increase in temperature and, at each temperature, Kab was the highest for sulfamethazine and the lowest for sulfadiazine."( Elucidation of the role of hydrophobic bonding in influencing intestinal absorption of model sulfonamides and revealing possible mechanism of drug absorption in rat model.
Chow, SL; Nagwekar, JB, 1993
)
0.29
"5 h) and the bioavailability was only 12."( Oral bioavailability of sulphonamides in ruminants: a comparison between sulphamethoxazole, sulphatroxazole, and sulphamerazine, using the dwarf goat as animal model.
Maas, R; Rátz, V; Semjén, G; van Miert, AS; Witkamp, RF, 1995
)
0.29
" The enhanced oral absorption consequently promoted the bioavailability of metformin from 43% to 65% in rats."( The first bioreversible prodrug of metformin with improved lipophilicity and enhanced intestinal absorption.
Huttunen, KM; Järvinen, T; Kemppainen, E; Laine, K; Leppänen, J; Mannila, A; Rautio, J; Vepsäläinen, J, 2009
)
0.35
"The ATP-binding cassette transporter P-glycoprotein (P-gp) is known to limit both brain penetration and oral bioavailability of many chemotherapy drugs."( A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
Ambudkar, SV; Brimacombe, KR; Chen, L; Gottesman, MM; Guha, R; Hall, MD; Klumpp-Thomas, C; Lee, OW; Lee, TD; Lusvarghi, S; Robey, RW; Shen, M; Tebase, BG, 2019
)
0.51

Dosage Studied

ExcerptRelevanceReference
" The results of this study failed to be of practical consequences, because the dosage applied and recommended by the producer significantly exceeded the minimum inhibition concentrations in serum and urine 3 h after administration."( [The influence of galenic and biologic factors on the bioavailability of Berlocombin].
Traeger, A; Truckenbrodt, J, 1984
)
0.27
" There are no consequences concerning the dosage of Berlocombin in bacterial infections during pregnancy."( [Studies on the pharmacokinetics of the compound preparation sulfamerazine/trimethoprim (Berlocombin-200) in pregnancy].
Müller, B; Nöschel, H; Peiker, G; Pischke, U; Schröder, S; Traeger, A, 1982
)
0.51
"The highly variegated complex of aspects relating to dosage calculation for veterinary drugs is explained and discussed by examples of Mebacid 200 and Mebacid tablets."( [Pharmacokinetic model studies of sulfamerazine in domestic mammals. 4. Mebacid tablet and Mebacid 200 dosage calculation problems].
Heinze, W; Losch, K; Mieth, K, 1980
)
0.54
" These data were used in dosage calculations for clinical testing."( [Pharmacokinetic studies of sulfamerazine-Na, sulfaperine-Na and sulfadimidine-Na in the hen].
Losch, K, 1980
)
0.56
"The objective of this Letter is to report the first (to our knowledge) in vivo proof of concept for a sulfenamide prodrug to orally deliver a poorly soluble drug containing a weakly-acidic NH-acid from a conventional solid dosage formulation."( An amide-based sulfenamide prodrug of gamma secretase inhibitor BMS-708163 delivers parent drug from an oral conventional solid dosage form in male beagle dog.
Clarke, W; Everlof, JG; Guarino, VR; Haskell, R; Lentz, KA; McDonald, I; Olson, RE; Wang, N, 2020
)
0.56
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Roles (2)

RoleDescription
antiinfective agentA substance used in the prophylaxis or therapy of infectious diseases.
drug allergenAny drug which causes the onset of an allergic reaction.
[role information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Drug Classes (3)

ClassDescription
pyrimidinesAny compound having a pyrimidine as part of its structure.
sulfonamideAn amide of a sulfonic acid RS(=O)2NR'2.
sulfonamide antibioticA class of sulfonamides whose members generally have bacteriostatic antibiotic properties.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Protein Targets (10)

Potency Measurements

ProteinTaxonomyMeasurementAverage (µ)Min (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Chain A, Beta-lactamaseEscherichia coli K-12Potency35.48130.044717.8581100.0000AID485294
Microtubule-associated protein tauHomo sapiens (human)Potency25.11890.180013.557439.8107AID1468
nuclear receptor subfamily 1, group I, member 3Homo sapiens (human)Potency13.33320.001022.650876.6163AID1224839
IDH1Homo sapiens (human)Potency1.29950.005210.865235.4813AID686970
cytochrome P450 2C9 precursorHomo sapiens (human)Potency0.00500.00636.904339.8107AID883
chromobox protein homolog 1Homo sapiens (human)Potency56.23410.006026.168889.1251AID540317
gemininHomo sapiens (human)Potency0.25930.004611.374133.4983AID624297
Histamine H2 receptorCavia porcellus (domestic guinea pig)Potency0.00500.00638.235039.8107AID883
Spike glycoproteinSevere acute respiratory syndrome-related coronavirusPotency5.01190.009610.525035.4813AID1479145
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Inhibition Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Bile salt export pumpHomo sapiens (human)IC50 (µMol)1,000.00000.11007.190310.0000AID1449628
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Biological Processes (22)

Processvia Protein(s)Taxonomy
fatty acid metabolic processBile salt export pumpHomo sapiens (human)
bile acid biosynthetic processBile salt export pumpHomo sapiens (human)
xenobiotic metabolic processBile salt export pumpHomo sapiens (human)
xenobiotic transmembrane transportBile salt export pumpHomo sapiens (human)
response to oxidative stressBile salt export pumpHomo sapiens (human)
bile acid metabolic processBile salt export pumpHomo sapiens (human)
response to organic cyclic compoundBile salt export pumpHomo sapiens (human)
bile acid and bile salt transportBile salt export pumpHomo sapiens (human)
canalicular bile acid transportBile salt export pumpHomo sapiens (human)
protein ubiquitinationBile salt export pumpHomo sapiens (human)
regulation of fatty acid beta-oxidationBile salt export pumpHomo sapiens (human)
carbohydrate transmembrane transportBile salt export pumpHomo sapiens (human)
bile acid signaling pathwayBile salt export pumpHomo sapiens (human)
cholesterol homeostasisBile salt export pumpHomo sapiens (human)
response to estrogenBile salt export pumpHomo sapiens (human)
response to ethanolBile salt export pumpHomo sapiens (human)
xenobiotic export from cellBile salt export pumpHomo sapiens (human)
lipid homeostasisBile salt export pumpHomo sapiens (human)
phospholipid homeostasisBile salt export pumpHomo sapiens (human)
positive regulation of bile acid secretionBile salt export pumpHomo sapiens (human)
regulation of bile acid metabolic processBile salt export pumpHomo sapiens (human)
transmembrane transportBile salt export pumpHomo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Molecular Functions (8)

Processvia Protein(s)Taxonomy
protein bindingBile salt export pumpHomo sapiens (human)
ATP bindingBile salt export pumpHomo sapiens (human)
ABC-type xenobiotic transporter activityBile salt export pumpHomo sapiens (human)
bile acid transmembrane transporter activityBile salt export pumpHomo sapiens (human)
canalicular bile acid transmembrane transporter activityBile salt export pumpHomo sapiens (human)
carbohydrate transmembrane transporter activityBile salt export pumpHomo sapiens (human)
ABC-type bile acid transporter activityBile salt export pumpHomo sapiens (human)
ATP hydrolysis activityBile salt export pumpHomo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Ceullar Components (13)

Processvia Protein(s)Taxonomy
basolateral plasma membraneBile salt export pumpHomo sapiens (human)
Golgi membraneBile salt export pumpHomo sapiens (human)
endosomeBile salt export pumpHomo sapiens (human)
plasma membraneBile salt export pumpHomo sapiens (human)
cell surfaceBile salt export pumpHomo sapiens (human)
apical plasma membraneBile salt export pumpHomo sapiens (human)
intercellular canaliculusBile salt export pumpHomo sapiens (human)
intracellular canaliculusBile salt export pumpHomo sapiens (human)
recycling endosomeBile salt export pumpHomo sapiens (human)
recycling endosome membraneBile salt export pumpHomo sapiens (human)
extracellular exosomeBile salt export pumpHomo sapiens (human)
membraneBile salt export pumpHomo sapiens (human)
virion membraneSpike glycoproteinSevere acute respiratory syndrome-related coronavirus
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (76)

Assay IDTitleYearJournalArticle
AID588459High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, Validation compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588459High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, Validation compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588459High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, Validation compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID588461High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, Validation compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588461High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, Validation compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588461High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, Validation compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID588460High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, Validation Compound Set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588460High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, Validation Compound Set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588460High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, Validation Compound Set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID504812Inverse Agonists of the Thyroid Stimulating Hormone Receptor: HTS campaign2010Endocrinology, Jul, Volume: 151, Issue:7
A small molecule inverse agonist for the human thyroid-stimulating hormone receptor.
AID504810Antagonists of the Thyroid Stimulating Hormone Receptor: HTS campaign2010Endocrinology, Jul, Volume: 151, Issue:7
A small molecule inverse agonist for the human thyroid-stimulating hormone receptor.
AID504749qHTS profiling for inhibitors of Plasmodium falciparum proliferation2011Science (New York, N.Y.), Aug-05, Volume: 333, Issue:6043
Chemical genomic profiling for antimalarial therapies, response signatures, and molecular targets.
AID1347407qHTS to identify inhibitors of the type 1 interferon - major histocompatibility complex class I in skeletal muscle: primary screen against the NCATS Pharmaceutical Collection2020ACS chemical biology, 07-17, Volume: 15, Issue:7
High-Throughput Screening to Identify Inhibitors of the Type I Interferon-Major Histocompatibility Complex Class I Pathway in Skeletal Muscle.
AID1347107qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh30 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347105qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for MG 63 (6-TG R) cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347424RapidFire Mass Spectrometry qHTS Assay for Modulators of WT P53-Induced Phosphatase 1 (WIP1)2019The Journal of biological chemistry, 11-15, Volume: 294, Issue:46
Physiologically relevant orthogonal assays for the discovery of small-molecule modulators of WIP1 phosphatase in high-throughput screens.
AID1347425Rhodamine-PBP qHTS Assay for Modulators of WT P53-Induced Phosphatase 1 (WIP1)2019The Journal of biological chemistry, 11-15, Volume: 294, Issue:46
Physiologically relevant orthogonal assays for the discovery of small-molecule modulators of WIP1 phosphatase in high-throughput screens.
AID1347098qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SK-N-SH cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347094qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for BT-37 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID651635Viability Counterscreen for Primary qHTS for Inhibitors of ATXN expression
AID1508630Primary qHTS for small molecule stabilizers of the endoplasmic reticulum resident proteome: Secreted ER Calcium Modulated Protein (SERCaMP) assay2021Cell reports, 04-27, Volume: 35, Issue:4
A target-agnostic screen identifies approved drugs to stabilize the endoplasmic reticulum-resident proteome.
AID1347093qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SK-N-MC cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347097qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Saos-2 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347092qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for A673 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347154Primary screen GU AMC qHTS for Zika virus inhibitors2020Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1347082qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: LASV Primary Screen - GLuc reporter signal2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347106qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for control Hh wild type fibroblast cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347099qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for NB1643 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347103qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for OHS-50 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1296008Cytotoxic Profiling of Annotated Libraries Using Quantitative High-Throughput Screening2020SLAS discovery : advancing life sciences R & D, 01, Volume: 25, Issue:1
Cytotoxic Profiling of Annotated and Diverse Chemical Libraries Using Quantitative High-Throughput Screening.
AID1347108qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh41 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1745845Primary qHTS for Inhibitors of ATXN expression
AID1347095qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for NB-EBc1 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347104qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for RD cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347091qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SJ-GBM2 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347096qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for U-2 OS cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347086qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lymphocytic Choriomeningitis Arenaviruses (LCMV): LCMV Primary Screen - GLuc reporter signal2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347102qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh18 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347090qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for DAOY cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347089qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for TC32 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347083qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: Viability assay - alamar blue signal for LASV Primary Screen2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347100qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for LAN-5 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347101qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for BT-12 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID26320pKa value is evaluated1983Journal of medicinal chemistry, Jul, Volume: 26, Issue:7
A simplified high-pressure liquid chromatography method for determining lipophilicity for structure-activity relationships.
AID13311Negative log of Langmuir's alpha constant (-log alpha), which is inversely proportional to the effective binding constant (protein binding)1983Journal of medicinal chemistry, Jul, Volume: 26, Issue:7
A simplified high-pressure liquid chromatography method for determining lipophilicity for structure-activity relationships.
AID599144Intrinsic solubility, log 1/S0 of the compound2008European journal of medicinal chemistry, Mar, Volume: 43, Issue:3
Computational aqueous solubility prediction for drug-like compounds in congeneric series.
AID599143Lipophilicity, log P of the compound2008European journal of medicinal chemistry, Mar, Volume: 43, Issue:3
Computational aqueous solubility prediction for drug-like compounds in congeneric series.
AID588211Literature-mined compound from Fourches et al multi-species drug-induced liver injury (DILI) dataset, effect in humans2010Chemical research in toxicology, Jan, Volume: 23, Issue:1
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
AID24211Compound is evaluated for ionization constant log k1983Journal of medicinal chemistry, Jul, Volume: 26, Issue:7
A simplified high-pressure liquid chromatography method for determining lipophilicity for structure-activity relationships.
AID670244Antimycobacterial activity against Mycobacterium tuberculosis H37Ra ATCC 25177 by microbroth dilution method2012Bioorganic & medicinal chemistry, Jul-01, Volume: 20, Issue:13
Synthesis and antimycobacterial activity of some phthalimide derivatives.
AID588213Literature-mined compound from Fourches et al multi-species drug-induced liver injury (DILI) dataset, effect in non-rodents2010Chemical research in toxicology, Jan, Volume: 23, Issue:1
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
AID64417Minimum inhibitory concentration (bacteriostatic) against Escherichia coli at pH 7.2 (Sauterne''s medium)1983Journal of medicinal chemistry, Jul, Volume: 26, Issue:7
A simplified high-pressure liquid chromatography method for determining lipophilicity for structure-activity relationships.
AID346025Binding affinity to beta cyclodextrin2009Bioorganic & medicinal chemistry, Jan-15, Volume: 17, Issue:2
Convenient QSAR model for predicting the complexation of structurally diverse compounds with beta-cyclodextrins.
AID588212Literature-mined compound from Fourches et al multi-species drug-induced liver injury (DILI) dataset, effect in rodents2010Chemical research in toxicology, Jan, Volume: 23, Issue:1
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
AID977599Inhibition of sodium fluorescein uptake in OATP1B1-transfected CHO cells at an equimolar substrate-inhibitor concentration of 10 uM2013Molecular pharmacology, Jun, Volume: 83, Issue:6
Structure-based identification of OATP1B1/3 inhibitors.
AID64418Minimum inhibitory concentration (bacteriostatic) against Escherichia coli at pH 7.41983Journal of medicinal chemistry, Jul, Volume: 26, Issue:7
A simplified high-pressure liquid chromatography method for determining lipophilicity for structure-activity relationships.
AID515780Intrinsic solubility of the compound in water2010Bioorganic & medicinal chemistry, Oct-01, Volume: 18, Issue:19
QSAR-based solubility model for drug-like compounds.
AID977602Inhibition of sodium fluorescein uptake in OATP1B3-transfected CHO cells at an equimolar substrate-inhibitor concentration of 10 uM2013Molecular pharmacology, Jun, Volume: 83, Issue:6
Structure-based identification of OATP1B1/3 inhibitors.
AID1449628Inhibition of human BSEP expressed in baculovirus transfected fall armyworm Sf21 cell membranes vesicles assessed as reduction in ATP-dependent [3H]-taurocholate transport into vesicles incubated for 5 mins by Topcount based rapid filtration method2012Drug metabolism and disposition: the biological fate of chemicals, Dec, Volume: 40, Issue:12
Mitigating the inhibition of human bile salt export pump by drugs: opportunities provided by physicochemical property modulation, in silico modeling, and structural modification.
AID576507Antiplasmodial activity against Plasmodium falciparum 3D7 infected in RBCs by firefly luciferase reporter gene assay2010Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9
Discovery of potent small-molecule inhibitors of multidrug-resistant Plasmodium falciparum using a novel miniaturized high-throughput luciferase-based assay.
AID1346986P-glycoprotein substrates identified in KB-3-1 adenocarcinoma cell line, qHTS therapeutic library screen2019Molecular pharmacology, 11, Volume: 96, Issue:5
A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
AID1346987P-glycoprotein substrates identified in KB-8-5-11 adenocarcinoma cell line, qHTS therapeutic library screen2019Molecular pharmacology, 11, Volume: 96, Issue:5
A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
AID588519A screen for compounds that inhibit viral RNA polymerase binding and polymerization activities2011Antiviral research, Sep, Volume: 91, Issue:3
High-throughput screening identification of poliovirus RNA-dependent RNA polymerase inhibitors.
AID540299A screen for compounds that inhibit the MenB enzyme of Mycobacterium tuberculosis2010Bioorganic & medicinal chemistry letters, Nov-01, Volume: 20, Issue:21
Synthesis and SAR studies of 1,4-benzoxazine MenB inhibitors: novel antibacterial agents against Mycobacterium tuberculosis.
AID1224864HCS microscopy assay (F508del-CFTR)2016PloS one, , Volume: 11, Issue:10
Increasing the Endoplasmic Reticulum Pool of the F508del Allele of the Cystic Fibrosis Transmembrane Conductance Regulator Leads to Greater Folding Correction by Small Molecule Therapeutics.
AID1159550Human Phosphogluconate dehydrogenase (6PGD) Inhibitor Screening2015Nature cell biology, Nov, Volume: 17, Issue:11
6-Phosphogluconate dehydrogenase links oxidative PPP, lipogenesis and tumour growth by inhibiting LKB1-AMPK signalling.
AID1159607Screen for inhibitors of RMI FANCM (MM2) intereaction2016Journal of biomolecular screening, Jul, Volume: 21, Issue:6
A High-Throughput Screening Strategy to Identify Protein-Protein Interaction Inhibitors That Block the Fanconi Anemia DNA Repair Pathway.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (492)

TimeframeStudies, This Drug (%)All Drugs %
pre-1990322 (65.45)18.7374
1990's19 (3.86)18.2507
2000's49 (9.96)29.6817
2010's77 (15.65)24.3611
2020's25 (5.08)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 41.66

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be strong demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index41.66 (24.57)
Research Supply Index6.26 (2.92)
Research Growth Index4.78 (4.65)
Search Engine Demand Index63.62 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (41.66)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials9 (1.76%)5.53%
Reviews10 (1.96%)6.00%
Case Studies8 (1.57%)4.05%
Observational0 (0.00%)0.25%
Other484 (94.72%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]